Therefore, comparing to traditional cancer immunotherapeutics, bsAbs targets CD47 along with other tumor antigens as a viable strategy for directing the synergistic benefits of combination therapy specifically toward tumor cells, has a potential to enhance security and efficacy. The gene discussed is CD47; the disease is neoplasm.